Canada · Delayed Price · Currency is CAD Neurothera Labs Statistics
Total Valuation
Neurothera Labs has a market cap or net worth of CAD 15.28 million. The enterprise value is 14.94 million.
| Market Cap | 15.28M |
| Enterprise Value | 14.94M |
Important Dates
The next estimated earnings date is Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurothera Labs has 84.90 million shares outstanding.
| Current Share Class | 84.90M |
| Shares Outstanding | 84.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | n/a |
| Float | 20.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.02 |
| PB Ratio | 17.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 1.44.
| Current Ratio | 1.35 |
| Quick Ratio | 1.29 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.90 |
Financial Efficiency
Return on equity (ROE) is -399.18% and return on invested capital (ROIC) is -109.66%.
| Return on Equity (ROE) | -399.18% |
| Return on Assets (ROA) | -71.32% |
| Return on Invested Capital (ROIC) | -109.66% |
| Return on Capital Employed (ROCE) | -165.38% |
| Weighted Average Cost of Capital (WACC) | 3.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.39 |
Taxes
In the past 12 months, Neurothera Labs has paid 26,051 in taxes.
| Income Tax | 26,051 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.00% in the last 52 weeks. The beta is -0.23, so Neurothera Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.23 |
| 52-Week Price Change | +20.00% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 10,225 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neurothera Labs had revenue of CAD 1.17 million and -5.65 million in losses. Loss per share was -0.08.
| Revenue | 1.17M |
| Gross Profit | 865,177 |
| Operating Income | -3.75M |
| Pretax Income | -5.96M |
| Net Income | -5.65M |
| EBITDA | -3.49M |
| EBIT | -3.75M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 2.33 million in cash and 1.28 million in debt, with a net cash position of 1.05 million or 0.01 per share.
| Cash & Cash Equivalents | 2.33M |
| Total Debt | 1.28M |
| Net Cash | 1.05M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 888,486 |
| Book Value Per Share | 0.00 |
| Working Capital | 664,993 |
Cash Flow
| Operating Cash Flow | -2.28M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 271,532 |
| Net Borrowing | 1.60M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 73.71% |
| Operating Margin | -319.74% |
| Pretax Margin | -507.48% |
| Profit Margin | n/a |
| EBITDA Margin | -297.08% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurothera Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -36.99% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neurothera Labs has an Altman Z-Score of -11.16 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.16 |
| Piotroski F-Score | 1 |